ASP0367 Development Program Update

October 27, 2021 2:00PM

Please join Jett Foundation and Astellas for a webinar to discuss the Phase 1b clinical trial studying ASP0367 in Duchenne muscular dystrophy. The trial is enrolling boys ages 8 to 16 years old who are taking a stable dose of steroids and have difficulty walking, regardless of mutation type.

ASP0367 is an oral investigational drug being tested in DMD. We will describe ASP0367, the clinical trial design, endpoints, inclusion and exclusion criteria, and other details about the trial.

Read their community letter for more information regarding ASP0367

Guest Speaker

Ha Tran, MD, MS, FAAP
Senior Medical Director
Global Medical Lead
Astellas Pharma

Ha Tran, MD, MS, FAAP is a Senior Medical Director and Global Medical Lead at Astellas Pharma US where her work focuses on mitochondrial and pediatric diseases. She is a board certified Pediatrician, specializing in Pediatric Nephrology, an Adjunct Clinical Assistant Professor at Stanford School of Medicine in the Department of Pediatrics. Dr. Tran has successfully led clinical trials in both medical devices and pharmaceuticals across various phases, in adults, children, and rare diseases.

Community Webinar Series - Better preparing for challenges in Duchenne

Jett Foundation invites all members of the Duchenne community to attend our Community Webinar Series! This series is focused on topics tailored to help individuals and families impacted by Duchenne learn more about care, clinical trials, resources, and support. We are committed to providing these 1-hour presentations to empower individuals and families with the tools and resources needed to be their own best advocates.

View Our Upcoming Educational Webinars

Please contact with any questions or if you’d like to become a future speaker at one of our community webinars. We look forward to having you participate in these virtual community engagement events!